Summary & Overview
HCPCS Level II S3849: Genetic Testing for Niemann-Pick Disease
HCPCS Level II code S3849 denotes genetic testing for Niemann-Pick disease, a set of inherited lysosomal storage disorders with significant diagnostic and care implications. Nationally, genetic confirmation informs prognosis, family counseling, and eligibility for disease-specific therapies or clinical trials, making accurate coding important for clinical documentation and claims processing. Key payers typically relevant for coverage and reimbursement discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
This publication provides a concise overview of the code's clinical context, payer coverage landscape, and the aspects of claims handling that influence access to testing. Readers will find benchmarks for common billing practices, summaries of payer coverage considerations where available, and a plain-language clinical context describing when genetic testing for Niemann-Pick disease is indicated. The content is intended for national audiences including billing professionals, laboratory managers, and policy analysts seeking clarity on how S3849 is used in practice and how it fits into broader genetic testing workflows.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, related codes, and detailed payer policies.
Billing Code Overview
HCPCS Level II code S3849 represents genetic testing for Niemann-Pick disease. This service involves laboratory-based molecular or biochemical testing to identify genetic variants or biochemical markers associated with Niemann-Pick disease, a group of rare lysosomal storage disorders.
-
Service Type: Genetic testing (diagnostic molecular testing)
-
Typical Site of Service: Clinical laboratory or outpatient laboratory specimen collection site
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with clinical features suggestive of Niemann‑Pick disease (such as hepatosplenomegaly, progressive neurodegeneration, failure to thrive, ataxia, vertical supranuclear gaze palsy, or unexplained lipid storage disorder) is referred for genetic testing. The clinical workflow begins with evaluation by a metabolic specialist, pediatric neurologist, or genetic counselor who documents family history, onset and progression of symptoms, and prior laboratory findings (e.g., abnormal sphingomyelinase activity for types A/B). A genetic testing order for S3849 is placed for targeted gene sequencing, multigene panel, or specific variant analysis of SMPD1 and other related genes (depending on suspected subtype). Specimen collection (typically blood or saliva) occurs in an outpatient clinic, genetic laboratory, or hospital outpatient department. The laboratory performs molecular testing, issues a report with identified pathogenic, likely pathogenic, or variant of uncertain significance findings, and the ordering clinician reviews results with the family to discuss diagnosis, prognosis, recurrence risk, and cascade testing for at‑risk relatives. Typical sites of service include hospital outpatient departments, specialized genetic clinics, and commercial clinical laboratories that receive mailed specimens.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing separately for physician interpretation of genetic test results distinct from the laboratory technical component |